Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas

作者: Iris Lavon , Daniel Zrihan , Bracha Zelikovitch , Yakov Fellig , Dana Fuchs

DOI: 10.1158/1078-0432.CCR-06-2050

关键词:

摘要: Purpose: Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these paired early progressive oligodendrogliomas. Experimental Design: 1p36, 19q13, 10q22-26, O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status were assessed 46 oligodendrogliomas from 23 patients. Results: In tumors, 60.8% low grade compared with only 17% low-grade tumors at recurrence. Of 17 described as pure 76.5% remained this lineage, regardless their grade, whereas others changed to astrocytic tumors. Oligoastrocytic had a significantly higher tendency transform All 1p/19q codeletions phenotypically unchanged, unlike mixed codeletions, which 83% cell lineage. 1p deletion, 80% oligodendroglial progression, 75% an intact phenotype. 10q loss was uncommon both The proportional gain 31% for 1p, 87.5% progression. Conclusions: Pure deletion tend retain phenotype profile no deletions or histology. MGMT more pronounced particularly 1p. These observations suggest late event therefore, chemosensitivity not necessarily related status.

参考文章(37)
Kenneth B. Fallon, Cheryl A. Palmer, Kevin A. Roth, L. Burton Nabors, Wenquan Wang, Mark Carpenter, Ruma Banerjee, Peter Forsyth, Keith Rich, Arie Perry, Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. Journal of Neuropathology and Experimental Neurology. ,vol. 63, pp. 314- 322 ,(2004) , 10.1093/JNEN/63.4.314
Bernard W. Futscher, Keizo Tano, Russell O. Pieper, Joseph F. Costello, Dawn M. Graunke, Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells Journal of Biological Chemistry. ,vol. 269, pp. 17228- 17237 ,(1994) , 10.1016/S0021-9258(17)32544-9
Carol Walker, Daniel G. Du Plessis, Kathy A. Joyce, Diane Fildes, Abigail Gee, Brian Haylock, David Husband, Trevor Smith, John Broome, Peter C. Warnke, Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Annals of Neurology. ,vol. 57, pp. 855- 865 ,(2005) , 10.1002/ANA.20496
A.M. Buccoliero, L. Arganini, F. Ammannati, P. Gallina, N. Di lorenzo, P. Mennonna, G.L. Taddei, Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. Journal of Chemotherapy. ,vol. 17, pp. 321- 326 ,(2005) , 10.1179/JOC.2005.17.3.321
Russell O. Pieper, Sonal Patel, Shelby A. Ting, Bernard W. Futscher, Joseph F. Costello, Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. Journal of Biological Chemistry. ,vol. 271, pp. 13916- 13924 ,(1996) , 10.1074/JBC.271.23.13916
J. Gregory Cairncross, Keisuke Ueki, Magdelena C. Zlatescu, David K. Lisle, Dianne M. Finkelstein, Robert R. Hammond, Jonathan S. Silver, Paul C. Stark, David R. Macdonald, Yasushi Ino, David A. Ramsay, David N. Louis, Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas Journal of the National Cancer Institute. ,vol. 90, pp. 1473- 1479 ,(1998) , 10.1093/JNCI/90.19.1473
Netta Levin, Iris Lavon, Bracha Zelikovitsh, Dana Fuchs, Felix Bokstein, Yakov Fellig, Tali Siegal, Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer. ,vol. 106, pp. 1759- 1765 ,(2006) , 10.1002/CNCR.21809
Roger E. McLendon, James E. Herndon, Bryan West, David Reardon, Rodney Wiltshire, B. K. Ahmed Rasheed, Jennifer Quinn, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Survival analysis of presumptive prognostic markers among oligodendrogliomas Cancer. ,vol. 104, pp. 1693- 1699 ,(2005) , 10.1002/CNCR.21362